Table 1 Analysis of canonical pathway and protein networks
From: Glial cell proteome using targeted quantitative methods for potential multi-diagnostic biomarkers
N | Ingenuity Canonical Pathways | -log (p-value) | Ratio | z-score | Down regulated % | No change % | Up regulated | No overlap with dataset % | Gene name |
|---|---|---|---|---|---|---|---|---|---|
1 | Protein ubiquitination pathway | 5.82 | 0.0784 | – | 4/268 (1) | 0/268 (0) | 17/268 (6) | 247/268 (92) | DNAJB1,DNAJC2,HSPB6,HSPB8,HSPD1,HSPE1,HSPH1,PSMC1,PSMC2,PSMC4,PSMD1,PSMD11,PSMD12,PSMD3,PSME1,SUGT1,THOP1,UBA1,UBE2O,USP24,USP8 |
2 | Protein kinase A signaling | 2.71 | 0.0494 | 0.243 | 14/385 (4) | 0/385 (0) | 5/385 (1) | 366/385 (95) | ADD3,CALM1,FLNA,GNG12,GNG2,GYS1,H10,ITPR3,MAP2K1,PLCB3,PPP1R10,PPP1R12A,PPP1R14A,PPP1R3D,PTPN12,PTPRJ,ROCK2,TGFB2,YWHAE |
3 | Sertoli cell-sertoli cell junction signaling | 5.23 | 0.0884 | – | 14/181 (8) | 0/181 (0) | 2/181 (1) | 165/181 (91) | ACTB,ACTN1,AKT1,AKT3,ILK,ITGB1,JAM2,JAM3,KRAS,MAP2K1,MAP2K3,MPP6,RALA,RRAS,TJP1,VCL |
4 | PI3K/AKT signaling | 4.23 | 0.0809 | − 1.387 | 10/173 (6) | 0/173 (0) | 4/173 (2) | 159/173 (92) | AKT1,AKT3,GRB2,GYS1,ILK,INPP5K,ITGB1,KRAS,LIMS1,MAP2K1,RALA,RRAS,SYNJ2,YWHAE |
5 | Leukocyte extravasation signaling | 2.69 | 0.0622 | 0 | 9/193 (5) | 0/193 (0) | 3/193 (2) | 181/193 (94) | ACTB,ACTN1,ARHGAP35,CD44,CD99,ITGB1,JAM2,JAM3,ROCK2,THY1,VCL,WASL |
6 | Systemic lupus erythematosus In T cell signaling pathway | 2.3 | 0.0556 | 0 | 8/216 (4) | 0/216 (0) | 4/216 (2) | 204/216 (94) | AKT1,AKT3,CD44,DNMT1,GRB2,KRAS,MAP2K1,MAP2K3,RALA,RND3,ROCK2,RRAS |
7 | IGF-1 signaling | 4.49 | 0.106 | − 0.707 | 7/104 (7) | 0/104 (0) | 4/104 (4) | 93/104 (89) | AKT1,AKT3,CCN1,CCN2,GRB10,GRB2,KRAS,MAP2K1,RALA,RRAS,YWHAE |
8 | 14–3-3-mediated signaling | 2.54 | 0.0714 | − 1 | 6/126 (5) | 0/126 (0) | 3/126 (2) | 117/126 (93) | AKT1,AKT3,GRB2,KRAS,MAP2K1,PLCB3,RALA,RRAS,YWHAE |
9 | HIPPO signaling | 2.45 | 0.0833 | – | 4/84 (5) | 0/84 (0) | 3/84 (4) | 77/84 (92) | CD44,PPP1R10,PPP1R12A,PPP1R14A,PPP1R3D,TP53BP2,YWHAE |
10 | ERK5 Signaling | 2.17 | 0.0833 | 0 | 3/72 (4) | 0/72 (0) | 3/72 (4) | 66/72 (92) | AKT1,KRAS,RALA,RPS6KA3,RRAS,YWHAE |
11 | Inhibition of ARE-mediated mRNA degradation pathway | 0.801 | 0.041 | − 1.342 | 3/122 (2) | 0/122 (0) | 2/122 (2) | 117/122 (96) | AKT1,AKT3,DDX6,PSME1,YWHAE |
12 | Necroptosis signaling pathway | 0.541 | 0.0327 | 1.342 | 1/153 (1) | 0/153 (0) | 4/153 (3) | 148/153 (97) | PLA2G4A,STAT1,TIMM13,TIMM8A,TOMM34 |
13 | Calcium signaling | 0.305 | 0.0253 | − 1 | 3/198 (2) | 0/198 (0) | 2/198 (1) | 193/198 (97) | ATP2B4,CACNA2D1,CALM1 (includes others),ITPR3,MYH14 |
14 | FAT10 signaling pathway | 3.16 | 0.222 | – | 1/18 (6) | 0/18 (0) | 3/18 (17) | 14/18 (78) | PSME1,SQSTM1,UBA1,UBA6 |
15 | mitochondrial dysfunction | 0.267 | 0.0242 | – | 2/165 (1) | 0/165 (0) | 2/165 (1) | 161/165 (98) | ATP5ME,CPT1A,GSR,NDUFAB1 |
16 | pentose phosphate pathway | 1.66 | 0.2 | – | 1/10 (10) | 0/10 (0) | 1/10 (10) | 8/10 (80) | PGD,TKT |
17 | DNA methylation and transcriptional repression signaling | 0.724 | 0.0588 | – | 1/34 (3) | 0/34 (0) | 1/34 (3) | 32/34 (94) | DNMT1,H4-16 |
18 | Apelin adipocyte signaling pathway | 0.256 | 0.0253 | – | 1/79 (1) | 0/79 (0) | 1/79 (1) | 77/79 (97) | GNA11,PRDX6 |
19 | Neuroprotective role of THOP1 in Alzheimer's disease | 0 | 0.0183 | – | 0/109 (0) | 0/109 (0) | 2/109 (2) | 107/109 (98) | THOP1,YWHAE |
20 | TCA Cycle II (Eukaryotic) | 0.363 | 0.0417 | – | 0/24 (0) | 0/24 (0) | 1/24 (4) | 23/24 (96) | IDH3A |
21 | Cell Cycle: G2/M DNA damage checkpoint regulation | 0.971 | 0.0612 | – | 0/49 (0) | 0/49 (0) | 3/49 (6) | 46/49 (94) | TGFB2 |